Cold Sore Ad Claims Review Poses Test For OTC Monograph Indications
Executive Summary
Council of Better Business Bureaus forwards review of ad claims for Aubio Life Sciences' monograph cold sore treatment to US FDA and FTC, after firm rejected advice to discontinue certain claims. Initial challenge was brought by GSK, which markets an NDA cold sore product.
You may also be interested in...
Carmex Cold Sore Treatment Claims Exceed Monograph Limit In NAD Review
Carma Labs’ Carmex Cold Sore Treatment claims did not mirror language in two OTC monographs for its active ingredients, the National Advertising Division says in a review of packaging and advertising claims challenged by GlaxoSmithKline's consumer business.
Mucinex Fast-Max Advertising Claim Exceeds Indications In NAD Review
Review was second in two years by the Council of Better Business Bureaus' National Advertising Division of a challenge to Reckitt Benckiser ad claims for its Mucinex cough/cold line made by Procter & Gamble, which markets competing products including Vicks NyQuil and DayQuil brands.
Athlete's Foot Firm Kicks Back On NAD Finding That Brand Is A Fungal Claim
Kramer Laboratories' claims for Fungi-Nail athlete's foot product referred to FDA and FTC after it refuses to comply with NAD's recommendation to modify the name. The firm, which agreed to modify packaging and commercial claims, was warned by FDA about the brand in 2005.